Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in heart failure patients with reduced left ventricular function and intraventricular conduction delay. However, individual outcomes vary significantly. This study sought to use a machine learning algorithm to develop a model to predict outcomes after CRT.
M
ultiple clinical trials have demonstrated the benefit of cardiac resynchronization therapy (CRT) on morbidity and mortality in heart failure (HF) patients with evidence of left ventricular dysfunction and intraventricular conduction delay. [1] [2] [3] [4] [5] However, ≈30% of patients, despite meeting criteria for implant, do not experience clinical benefit from CRT. [6] [7] [8] [9] Current American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) and European Society of Cardiology (ESC) guidelines emphasize bundle branch block (BBB) morphology and QRS duration for patient selection, with the strongest recommendations for CRT implant in patients with left BBB (LBBB) and QRS duration ≥150 ms. 9, 10 Recent analyses from registries have demonstrated that BBB morphology and QRS duration also predict long-term outcomes after CRT; patients with LBBB and QRS of 150 ms or greater experienced fewer deaths and readmissions than other patients receiving CRT. 11, 12 However, clinical experience shows that not all patients with LBBB and wide QRS have a good outcome after CRT. 13 Conversely, some patients with non-LBBB and QRS duration >150 ms or others with LBBB but QRS duration <150 ms experience improvement. 14, 15 Additionally, device implantation carries risk with coronary sinus complications occurring in 2% of patients, the need for device failure requiring revision in as many as 5% of patients, and a 6-month cumulative incidence of any complication as high as 10%. [16] [17] [18] Therefore, estimating a patient's outcome after CRT is an important part of the shared decision-making process before implantation. In fact, the ACC/AHA/HRS guideline calls for shared decision-making with patients during the informed consent process. 9 Unfortunately, the patient characteristics that are outlined in the ACC/AHA/HRS guidelines to estimate an individual patient's outcome, BBB morphology and QRS duration, lack precision. The combination of these characteristics estimates a hazard ratio (HR) of only 1.5 between those patients with the best and worst mortality and <2 for HF admission. 11 The Precision Medicine Initiative asks our profession to avoid oversimplification and to take individual variability into account to improve this shared decision-making process. 19 A call to achieve precision cardiovascular care has been described. 20 The tools outlined included improved analytic and bioinformatics methods to integrate data from the electronic health record to assist clinicians at the bedside. Machine learning is a computational discipline focused on building algorithms that model or recognize complex patterns or characteristics within large amounts of data. Machine learning algorithms have been applied within cardiology to understand the complex genetics of coronary artery disease, to improve prediction of 30-day
WHAT IS KNOWN?
• Cardiac resynchronization therapy provides a clear benefit to heart failure patients with reduced left ventricular function and intraventricular conduction delay.
• Individual outcomes after cardiac resynchronization therapy vary significantly.
WHAT THE STUDY ADDS?
• A random forest algorithm was used to develop a model that significantly improved the ability to discriminate outcomes after cardiac resynchronization therapy.
• The use of machine learning algorithms like the random forest may improve shared decision-making with patients and lead to improvements in precision cardiovascular medicine.
readmission after coronary intervention, and to classify HF with preserved ejection fraction. [21] [22] [23] Machine learning algorithms have also been used to generate models to predict echocardiographic response to CRT; however, to our knowledge, they have not been used to predict clinical outcomes like mortality and HF hospitalizations. [24] [25] [26] We hypothesized that machine learning algorithms may produce a model that discriminates mortality and the composite end point of mortality or HF hospitalization after CRT implantation for individual patients better than the widely used clinical discriminators of BBB morphology and QRS duration. We tested this hypothesis with data from the COMPANION trial (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure).
METHODS

Study Population
The design and primary results of the COMPANION trial have been published elsewhere. 1, 27 The authors were given permission by the COMPANION executive committee to use the trial data. However, they do not control access to the data and cannot make the data, analytic methods, and study materials available to other researchers for purposes of reproducing the results or replicating the procedure. Briefly, COMPANION was a randomized, controlled multicenter trial that included 1520 patients with advanced HF with left ventricular ejection fraction of ≤35% randomized in a 1:2:2 ratio to receive optimal pharmacological therapy alone, or in combination with CRT-pacemaker (CRT-P) or CRT-defibrillator (CRT-D). All enrolled patients had New York Heart Association (NYHA) class III or IV symptoms.
Study Design
The present study included one cohort for model development and a second for validation ( Figure 1 ). Machine learning models were developed using the CRT-P cohort of the COMPANION trial. Limiting model development to this cohort allowed for isolation of the benefits of CRT without the confounding effect of defibrillation. The best performing model was then validated in the CRT-D cohort.
Human Subjects Approval
The COMPANION executive committee and the institutional review board of the University of Wisconsin-Madison approved the retrospective use of the deidentified data from the trial for the present study (IRB No. 2015-0657).
Model Development
Patient Selection
The CRT-P arm of COMPANION consisted of 617 patients; however, per the primary trial report, CRT implantation was successful in 539 patients. 1 With the data available to the authors, successful implant could be confirmed in 481 patients; therefore, these patients were used for model development. This model development cohort was identified before merging preimplant data with outcomes to avoid selection bias.
Machine Learning Algorithms
Model development included trials of several machine learning algorithms available in the Waikato Environment for Knowledge Analysis, an open-source unified workbench that allows access to state-of-the-art machine learning algorithms. 28 Algorithms tested included Naive Bayes classifier, sequential minimal optimization for training a support vector machine, decision lists, J48 decision tree, and the random forest (RF) algorithm. We also compared the performance of the machine learning algorithms to a standard multivariate logistic regression model. Forty-five preimplant features (Table) were used to characterize the patients. 
Model Selection
The algorithms were used to create models to predict the composite end point of the absence of death or HF hospitalization at 12 months post-randomization in the 481 CRT-P patients. Ten-fold cross-validation was used to evaluate the predictive performance of each model by dividing the training data set into 10 mutually exclusive subsets, 9 of which were used for training and 1 for evaluation. This was repeated 10×, thereby using 10 different, but overlapping training sets, and 10 unique testing sets.
Receiver operating characteristic curve analysis was used to evaluate the performance of each model. Comparisons between the area under the curve (AUC) for the receiver operating characteristic curve of each model were made using a paired t test based on fold-by-fold AUC during the cross-validation. The classification performance at particular cutoff thresholds was also evaluated according to its sensitivity, specificity, positive predictive value, and negative predictive value.
The most informative model based on receiver operating characteristic curve AUC was the one produced using the RF algorithm. This finding is consistent with other studies in clinical data sets in which the RF outperformed other algorithms. 29, 30 The RF algorithm is an ensemble of decision trees. 31, 32 A full discussion of this method is beyond the scope of this article. Briefly, decision trees repeatedly dichotomize a data set based on their determination of the most informative feature. At a given node (ie, decision point), the algorithm finds the feature (eg, QRS duration, QRS morphology, patient age, etc) and threshold value that best partitions the cases into 2 subsets that differ in class distribution (did or did not experience and event in this example). The procedure continues recursively until each terminal node consists mostly of cases of one class. The resulting terminal nodes are each assigned the label that is the majority class of the cases in that node. In a RF, decision trees are built from a training set constructed by sampling several cases with replacement at random from the data and sampling several features at random. This process is repeated to produce many decision trees (a forest) whose predicted outcomes are combined into a single value. Test cases are labeled by majority vote of the resulting trees.
Model Validation
As depicted in Figure 1 , the best performing model was applied to the 595 patients with CRT-D for validation. The CRT-D population was partitioned 2 ways (1) according to a combination of BBB morphology and QRS duration; BBB/ QRS 1, LBBB and QRS duration of ≥150 ms; BBB/QRS 2, LBBB and QRS duration <150 ms or non-LBBB and QRS duration of ≥150 ms; and BBB/QRS 3, non-LBBB with QRS duration <150 ms; and (2) according to quartiles based on the probability of remaining event free as predicted by the RF model; quartile 1, highest probability of remaining event free to quartile 4, lowest probability.
Event driven outcomes were then assessed for each subgroup. The outcomes assessed were (1) the composite of all-cause mortality or HF hospitalization and (2) all-cause mortality alone.
Comparison of Descriptive Statistics and Outcomes Across Subgroups
The differences in demographic, ECG, echocardiographic, and clinical characteristics for each partition were compared using either χ 2 or Fisher exact tests for categorical variables and either t test or ANOVA for continuous variables. Allcause mortality or HF hospitalizations and all-cause mortality alone were compared across subgroups for each method of partitioning with Kaplan-Meier analysis. Differences in events between subgroups were evaluated using the log-rank test. Unadjusted Cox proportional hazards models were used to determine the independent association between subgroup and outcomes. Statistical analyses were performed using R version 3.2.2 (2015-08-04).
RESULTS
Model Development
The characteristics of the patients used for model development are shown in Table I in the Data Supplement. One hundred twenty-nine patients (27%) experienced a death or HF hospitalization within 12 months of randomization. Patients who experienced this end point were significantly more likely to have the following characteristics: larger left ventricular end-diastolic dimension, a shorter QRS duration, male sex, ischemic cause for their cardiomyopathy, NYHA class IV, a shorter 6-minute walk distance, not on a β-blocker, history of renal disease, and a history of intermittent atrial arrhythmia. The RF algorithm with 550 trees produced a model with the best AUC (0.74; 95% CI, 0.72-0.76). The improvement in AUC for the RF model was statistically significant compared with that of the other models (P<0.001; Figure 2 for comparison to multivariate logistic regression and sequential minimal optimization for training a support vector machine). The RF model shown in Figure 2 , operating at a threshold of 0.76 (patients with a model output of ≥0.76 predicted to have no event), had a sensitivity of 52%, a negative predictive value of 38%, a specificity of 80%, and a positive predictive value of 88%.
Validation of Model
The characteristics of the 595 patients in the CRT-D cohort as well as the subgroups defined by BBB morphology/QRS duration and the RF model are shown in Table II in the Data Supplement. Although both schemes created variation between subgroups in some features, there were significant differences across RF model quartiles for 33/45 features compared with only 12/45 for subgroups defined by BBB morphology/QRS duration. The model performance in the CRT-D validation cohort was similar to that seen in the CRT-P cohort used for development. Operating at a threshold of 0.76 (patients with a model output of ≥0.76 predicted to have no event) the model had a sensitivity of 51% in the CRT-D cohort (compared with 52% in training set), had a negative predictive value of 37% (compared with 38%), a specificity of 77% (compared with 80%), and a positive predictive value of 85% (compared with 88%).
In the CRT-D cohort of the COMPANION trial, there 214 events for the composite end point of death or HF hospitalization over a median follow-up of 15.7 months. The Kaplan-Meier analysis for this outcome for each method of partitioning is shown in Figure 3A and 3B with HRs for each subgroup (referenced to either LBBB and QRS ≥150 ms for BBB morphology/ QRS duration or quartile 1 for the RF model) shown in Figure 3C . There was a significant difference in the distribution of events across subgroups generated by BBB morphology/QRS duration ( Figure 3A ; log-rank P=0.005); however, there was no significant difference in events between those patients with BBB morphology/QRS duration subgroup 2 (BBB/QRS 2: non-LBBB and QRS ≥150 ms or LBBB and QRS <150 ms,) and those with BBB morphology/QRS duration subgroup 3 (BBB/QRS 3: non-LBBB and QRS <150 ms). The RF model produced subgroups with a graded increase in events moving from quartile 1 through quartile 4 with patients in quartile 4 having a 3-fold increase in events compared with those in quartile 1 (HR, 3.26; 95% confidence interval [CI], 2.13-5.00).
The Kaplan-Meier analysis for all-cause mortality alone for both methods of partitioning is shown in Figure 4A and 4B with HR for each subgroup (referenced to either LBBB and QRS ≥150 ms or quartile 1) shown in Figure 4C . In the CRT-D cohort, there were 105 deaths over a median follow-up of 15.7 months. For the subgroups based on BBB morphology/QRS duration, the difference in the survival distribution across subgroups did not reach significance (log-rank P=0.08). Compared to patients with LBBB and QRS ≥150 ms, there was a significant decrease in survival for patients with non-LBBB and QRS ≥150 ms or LBBB and QRS <150 ms (HR, 1.58; 95% CI, 1.04-2.40) but only a trend toward decreased survival in patients with non-LBBB and QRS <150 ms (HR, 1.42; 95% CI, 0.82-2.48). The results for subgroups created using the RF model are shown in Figure 5B . The difference in survival distribution across subgroups reached significance (P<0.0001) with a nearly 8-fold increase in mortality in quartile 4 compared with quartile 1 (HR, 7.96; 95% CI, 3.60-17.56).
The RF model reclassified a significant number of patients compared with classification based on BBB morphology/QRS duration ( Figure 5 ). Over one-third of the patients in RF quartile 4 (52 patients)-the patients predicted to have the worst outcomes by this modelhad a LBBB morphology and QRS duration ≥150 ms, that is, characteristics that would predict the best outcome using BBB morphology and QRS duration alone. Conversely, over 20% of the patients in RF quartile 1 (32 patients) did not have LBBB morphology and QRS duration of ≥150 ms. The 52 patients with LBBB morphology and QRS duration ≥150 ms in RF quartile 4 experienced significantly more events compared with the 32 patients without LBBB and QRS duration ≥150 ms in RF quartile 1 (HR, 2.42; 95% CI, 1.09-5.34 for all-cause mortality or HF hospitalization; HR, 6.62; 95% CI, 1.55-28.30 for all-cause mortality).
DISCUSSION
Using a RF algorithm, we developed, validated, and applied a model to predict CRT outcomes based on preimplant characteristics in a retrospective analysis of the COMPANION trial. Compared with prediction methodology based on BBB morphology and QRS duration, our data demonstrates that the RF model more precisely predicted patient outcomes in the COMPANION trial. This improved prediction included reclassification of patients from a group expected to have a better outcome based on BBB morphology and QRS duration to a more precise group based on the RF model. Ideally, treatment recommendations for patients will include individualized outcome estimates. However, historically, this has not been feasible and outcome estimates have been extrapolated from large clinical trial outcomes. Although these are effective at predicting outcomes at the population level, there remains a significant gap in capability to predict an outcome for an individual patient. Machine learning is a powerful, computational method that could allow for improved description of phenotypes and development of decision support tools to predict clinical outcomes and better inform shared decision-making with patients.
For CRT, there is substantial variation in response and outcomes, and several studies have investigated predictors that contribute to this variation. [33] [34] [35] [36] [37] [38] [39] Current ACC/AHA/HRS and ESC guidelines 9,10 provide recommendations largely based on BBB morphology and QRS duration. Recent analyses have shown that LBBB morphology and QRS duration ≥150 ms do predict allcause mortality and HF hospitalizations at a population level after CRT. 11, 12 Here, when applied retrospectively to patients from the COMPANION trial, partitioning the CRT-D cohort according to BBB morphology and QRS duration did discriminate outcomes. Patients without the combination of LBBB and QRS duration ≥150 ms experienced a 1.5-fold increase in both end points evaluated: the composite end point of death or HF hospitalization and death alone, compared to those with LBBB and QRS duration ≥150 ms. This result is very similar to previously published data about outcomes based on BBB morphology and QRS duration. 11 However, the RF model provided greater differentiation across subgroups (Figures 3 and 4) . For example, the 148 patients predicted to have the best outcome in the RF model, that is, those in quartile 1, experienced 7 deaths during in-trial follow-up compared with 50 deaths in the 150 patients in quartile 4 >4-fold increase in events from quartile 1 to quartile 4. In contrast, using BBB morphology and QRS duration, the difference in mortality across subgroups was not as robust and did not reach statistical significance.
Additionally, the RF model reclassified a significant number of patients from one subgroup based on BBB morphology and QRS duration to a more precise group based on the RF model. Thirty-two patients (22%) in quartile 1 did not have a LBBB and QRS duration ≥150 ms. Of these 32 patients, who would have been expected to have a worse outcome based solely on BBB mor- phology and QRS duration, only 2 experienced death during follow-up. In contrast, 52 of the 150 patients (35%) in quartile 4, did have LBBB and QRS duration ≥150 ms and accounted for 40% of the deaths (20/50) in this quartile. This reclassification demonstrates how a model that incorporates a broad spectrum of clinical data (demographic data, ECG data, echocardiogram, patient history) can improve discussions with individual patients. Based on BBB morphology and QRS duration, these 52 with LBBB and QRS duration ≥150 ms patients would have been predicted to have a relatively good outcome before implant. However, when taken together with other available data, a different expectation could have been communicated to the patient before implant.
The RF model and the reclassification observed with the model also provides an opportunity to understand what features (or variables) may contribute to the varied outcomes observed. One method to understand the feature importance in the data set is using its relative information gain. 28 This can be quantified by how well a feature reduces impurity in the data set. In this regard, an ideal feature would split the data set perfectly according to the classification, that is, in this case, the ideal feature would split the data set into those patients who experienced death or HF at 12 months post-randomization and those who did not. For this data set ( Figure I in the Data Supplement), the 5 most important features based on information gain were (1) a history of renal disease, (2) the time from HF diagnosis, (3) NYHA class, (4) QRS duration, and (5) a history of intermittent atrial arrhythmia. The importance of these features in the RF model becomes apparent when looking at the differences between RF quartiles (Table IIB in the Data Supplement). This table demonstrates a marked increase in the percentage of patients with a history of renal disease, a shorter duration of HF before implant, more patients with NYHA class III symptoms, a longer QRS duration and fewer patients with a history of intermittent atrial arrhythmias when moving from RF quartile 1 to RF quartile 4.
Analyzing the patients reclassified with the RF model offers another opportunity to assess features that should be considered when attempting to estimate outcomes for individual patients. Patients in the BBB/ QRS subgroups 2 and 3 who were in RF quartile 1 (the 32 patients shown in Figure 5 ) were very similar to BBB/ QRS subgroup 1 patients in RF quartile 1. There were statistically significant differences in only 4 features between these groups: QRS duration and percent of patients with LBBB as a consequence of the BBB/QRS partitioning, left ventricular ejection fraction, and the number of patients with a history of peripheral vascular disease (Table III in the Data Supplement) . However, patients in BBB/QRS subgroup 1 who were in RF quartile 4 (the 52 patients in Figure 5 ) had statistically significant differences from BBB/QRS subgroup 1 patients in RF quartile 1 in 26 different features. These included 4 of the 5 features identified based on information gain above (all except QRS duration as would be expected). Other features with statistical significant differences reaching P<0.0001 included age, an ischemic cause, and other features associated with a history of ischemic heart disease, 6-minute walk distance, PR interval, and whether or not patients were on a β-blocker.
Interestingly, many of these features (QRS duration, NYHA class, history of renal disease, ischemic disease and atrial arrhythmias, and PR interval) have been described elsewhere as influencing CRT outcomes. 14, 35, [40] [41] [42] [43] Additionally, there has been a recent article describing the influence of comorbid conditions on CRT outcomes. 13 However, to our knowledge, to date there has not been a model developed to bring together all of these features.
With the increasing use of electronic health records, the prospective application of models developed with machine learning algorithms is quickly becoming possible. The use of such models will represent a paradigm shift that will bring precision medicine closer to reality. An important element in shared decision-making with an individual patient is understanding the best available evidence for the risks and benefits of a therapy for that patient. 44 For CRT, BBB morphology and QRS duration are currently used to guide these discussions without incorporating other clinical characteristics and comorbid conditions into a decision-making tool. However, one can envision a model like the one developed with the RF algorithm being applied via the electronic medical record to each patient presenting for a preimplant discussion. The predicted probability of an event could be shared with the patient and would serve as a critical element to assist the implanter in developing guidance for that patient and to facilitate shared decision-making.
In many instances, traditional logistic regression analysis may be the best model to make this prediction. This is especially true if data sets are smaller and contain limited features. However, this is only one tool, and as data sets grow larger and additional features are added, other methods may improve prediction. If we expand our choices to include 10 or more additional leading machine learning algorithms, we increase our chances of finding a model that is suitable for the data in question. Therefore, machine learning algorithms may play an important role in precision cardiology.
Limitations
The current study used data from the COMPANION trial and included follow-up of patients for only 16 months. Therefore, it is not known whether a similar result would be obtained if follow-up was longer. The COMPANION trial also enrolled only patients with NYHA class III and IV symptoms. Therefore, the results of this study only extend to those with advanced HF. It is unknown whether these results are applicable to patients with NYHA I or II symptoms.
The models developed here rely on 45 features that are easily obtainable from the clinical history, ECG data or basic echocardiographic features. The features were consistently described in both the model development (CRT-P) and validation (CRT-D) cohorts as both cohorts were from the same clinical trial. Our finding that the RF algorithm produced the best model for a data are consistent with other work using machine learning algorithms to predict clinical end points 29, 30 ; however, as has been pointed out previously with RFs, consistency in the reporting of features has limited their utility within cardiology to date. 45 Moving forward, developing consistent standards for the definition of features will be necessary to fully use the strength of machine learning algorithms. Finally, the models developed here use the data from one clinical trial. Although the trial was multicenter, because of the retrospective nature of this study, potential unidentified confounders may exist. Therefore, the results of this study should be validated in additional study populations.
Conclusions
In this study, we used a machine learning algorithm to develop and validate a model to discriminate clinical outcomes with CRT using easily obtainable preimplantation characteristics. Classification of patients using models like this may improve patient selection for CRT and enhance the shared decision-making process with patients before implant. As clinical data sets expand, application of machine learning algorithms will lead to further improvements in precision cardiovascular medicine.
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